<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337829</url>
  </required_header>
  <id_info>
    <org_study_id>15-H-0016</org_study_id>
    <nct_id>NCT02337829</nct_id>
  </id_info>
  <brief_title>Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL</brief_title>
  <official_title>A Phase II Study Using ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the response to acalabrutinib in patients with chronic lymphocytic
      leukemia (CLL) or small lymphocytic lymphoma (SLL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have
      relapsed/refractory disease or treatment naive deletion 17p.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response based on overall response rate</measure>
    <time_frame>Cycle 1 (28 Days) to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>to undergo superficial lymph node biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>to undergo bone marrow biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <description>Patients undergo lymph node biopsies</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <description>Patients undergo bone marrow biopsies</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 years of age and older with histologically confirmed disease.

          -  Active disease as defined by at least one of the following (IWCLL consensus criteria):

               -  Weight loss ≥10% within the previous 6 months

               -  Extreme fatigue

               -  Fevers of greater than 100.5ºF for ≥2 weeks without evidence of infection

               -  Night sweats for more than one month without evidence of infection

               -  Evidence of progressive marrow failure as manifested by the development of, or
                  worsening of, anemia and/or thrombocytopenia

               -  Massive or progressive splenomegaly

               -  Massive nodes or clusters or progressive lymphadenopathy

               -  Progressive lymphocytosis with an increase of &gt;50% over a 2 month period, or an
                  anticipated doubling time of less than 6 months

               -  Compensated autoimmune hemolysis

          -  Relapsed/Refractory CLL or treatment naïve CLL patients with 17p deletion, TP53
             mutation, or NOTCH1 mutation

          -  Agreement to use acceptable methods of contraception during the study and for 30 days
             after the last dose of study drug if sexually active and able to bear or beget
             children.

          -  Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty and serial biopsies.

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject privacy regulations).

        Exclusion Criteria:

          -  Radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or investigational
             products in the last 4 weeks.

          -  Richter's transformation. Autoimmune hemolytic anemia or thrombocytopenia requiring
             steroid therapy. Impaired hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acerta Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>1-888-292-9613: acertamc@dlss.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/refractory CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>Btk</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphocytic</keyword>
  <keyword>ACP-196</keyword>
  <keyword>acalabrutinib</keyword>
  <keyword>Treatment naive CLL with 17p deletion, TP53 mutation or NOTCH1 mutation</keyword>
  <keyword>17p deletion</keyword>
  <keyword>TP53 mutation</keyword>
  <keyword>NOTCH1 mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

